OLX702A

**OLX702A** is a GalNAc-conjugated asymmetric small interfering RNA targeting **mitochondrial amidoxime reducing component 1** to silence hepatic **MTARC1** expression. It was originated by **OliX Pharmaceuticals** and is being developed for **metabolic-associated steatohepatitis** with additional preclinical rationale in **obesity**, including reported synergy with GLP-1 agonists such as semaglutide. The drug is formulated as a **subcutaneous injection** intended for infrequent dosing, including once-every-3-months administration, and entered **Phase 1** clinical testing in Australia. In 2025, **Eli Lilly** licensed rights to further develop and commercialize the program.